Skip to main content

Table 1 Demographics and baseline disease characteristics

From: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

  Total (N = 57)
Age, n (%)
 < 65 46 (81)
 ≥ 65 11 (19)
 Mean (SD) 55 (9)
 Median (range) 54 (27 to 72)
Sex, n (%)
 Male 34 (60)
 Female 23 (40)
ECOG performance status, n (%)
 0 21 (37)
 1 27 (47)
 2 9 (16)
ISS stage, n (%)
 I 15 (26)
 II 14 (25)
 III 21 (37)
 Unknown 7 (12)
Type of myelomaa, n (%)
 IgG 25 (44)
 IgA 15 (26)
 Light chain 17 (30)
  Kappa 7 (12)
  Lambda 10 (18)
Time from initial MM diagnosis, years
 Mean (SD) 4 (2)
 Median (range) 4 (1 to 9)
Number of prior lines of therapy, n
 Mean (SD) 3 (2)
 Median (range) 3 (1 to 9)
Autologous stem cell transplantation, n (%) 10 (18)
Prior therapies, n (%)
 Proteasome inhibitors 39 (68)
  Bortezomib 39 (68)
  Carfilzomib 1 (2)
 Immunomodulatory agents 49 (86)
  Lenalidomide 25 (44)
  Pomalidomide 2 (4)
  Thalidomide 39 (68)
 Proteasome inhibitors + immunomodulatory agents 34 (60)
  1. ECOG Eastern Cooperative Oncology Group, IgA immunoglobulin A, IgG immunoglobulin G, ISS International Staging System, SD standard deviation
  2. aThe type of myeloma was assessed per International Myeloma Working Group criteria for diagnosis of multiple myeloma [23]